Last updated: August 22, 2026
Lodine is the former U.S. brand name for etodolac, a nonsteroidal anti-inflammatory drug used for osteoarthritis and rheumatoid arthritis. Its commercial trajectory is typical of an older small-molecule medicine: initial branded growth, loss of exclusivity, broad generic substitution, declining brand relevance, and limited public visibility into product-level revenue. Lodine is no longer a meaningful branded growth asset in the U.S. pharmaceutical market.
What is Lodine and who marketed it?
Lodine contains etodolac, a preferential cyclooxygenase-2 inhibitor within the NSAID class. The original immediate-release product was marketed in 200 mg, 300 mg and 400 mg strengths. Lodine XL provided extended-release once-daily dosing and was indicated for osteoarthritis and rheumatoid arthritis treatment.[1]
| Attribute |
Lodine |
| Active ingredient |
Etodolac |
| Drug class |
NSAID |
| Original developer/marketer |
Wyeth-Ayerst Laboratories |
| U.S. regulatory status |
Historically approved prescription product |
| Main indications |
Osteoarthritis and rheumatoid arthritis |
| Dosage forms |
Immediate-release tablets; extended-release tablets |
| Current competitive form |
Generic etodolac |
| Biologic status |
Small molecule; biosimilar pathway does not apply |
| Commercial position |
Legacy product with generic competition |
Wyeth became part of Pfizer in 2009. Pfizer’s acquisition expanded its portfolio of legacy and mature products, but public Pfizer filings did not separately disclose Lodine revenue as a standalone reporting line.[2]
When did Lodine lose exclusivity?
Lodine lost commercial exclusivity after expiration of its original patent and regulatory exclusivity protections. The relevant competitive event was the entry of generic etodolac, which converted the product from a branded NSAID into a multisource generic medicine.
The exact commercial erosion date is more important than the original patent date. Once multiple generic manufacturers entered, pharmacy benefit managers and wholesalers had strong incentives to substitute generic etodolac for Lodine. The product’s clinical differentiation was limited because etodolac competed against numerous low-cost NSAIDs, including naproxen, ibuprofen, diclofenac and meloxicam.
Historical exclusivity timeline
| Period |
Commercial event |
Market effect |
| Mid-1980s |
U.S. introduction of etodolac under the Lodine brand |
Branded launch into the prescription NSAID market |
| 1990s |
Expansion of dosage forms, including extended-release Lodine XL |
Improved dosing convenience but limited long-term differentiation |
| Late 1990s to 2000s |
Generic etodolac approvals and market entry |
Rapid price and share erosion |
| 2009 |
Pfizer completed acquisition of Wyeth |
Lodine became part of Pfizer’s mature-product portfolio |
| 2010s |
Generic etodolac became the principal U.S. supply channel |
Brand economics weakened further |
| Current market |
Lodine has limited or no material branded U.S. market presence |
Commercial value resides primarily in generic supply |
The U.S. Food and Drug Administration’s Orange Book records approved drug products and listed patents where applicable. Current commercial activity is centered on abbreviated new drug applications for etodolac rather than a protected Lodine franchise.[3]
What patents protected Lodine?
Lodine’s core protection came from patents covering etodolac and related pharmaceutical compositions. Those rights are now expired or commercially exhausted in the United States. No active patent estate appears to preserve a meaningful branded monopoly for conventional etodolac tablets.
The historical patent position had several possible layers:
- Composition-of-matter protection for etodolac.
- Pharmaceutical composition claims covering etodolac dosage forms.
- Formulation claims associated with extended-release delivery.
- Method-of-use claims for treating inflammatory and rheumatic conditions.
- Regulatory exclusivity connected with the original approval.
The commercial significance of the formulation and method-of-use layers was limited by the age of the product and the availability of generic immediate-release etodolac. Even where an extended-release formulation had separate intellectual-property protection, generic competition could develop around other approved strengths, dosage forms or labeling strategies.
What formulations were protected by Lodine patents?
The most commercially relevant formulation distinction was between conventional immediate-release etodolac tablets and Lodine XL extended-release tablets. Extended-release technology could support separate patent claims, but it did not prevent generic competition against the immediate-release product.
Formulation protection for older oral NSAIDs is usually vulnerable to several pressures:
- Generic manufacturers can target non-protected strengths.
- A generic may avoid a narrow release-profile claim.
- Physicians can substitute another etodolac dosage form.
- Payers often prefer the lowest-cost clinically acceptable product.
- The active ingredient itself is already familiar to prescribers.
No current formulation patent appears to create a durable premium market for Lodine in the United States.
What is the Orange Book status of Lodine?
Lodine’s Orange Book relevance is historical rather than commercial. The Orange Book continues to provide a regulatory record for approved etodolac products and patent certifications, but the presence of a historical brand or legacy listing does not establish current market exclusivity.
A generic applicant seeking approval for etodolac may use an ANDA pathway and certify against listed patents under Paragraph I, II, III or IV. For a mature product such as etodolac, the commercially important scenario is usually that listed patents have expired, are no longer blocking, or do not cover the generic applicant’s proposed product.
Were there Paragraph IV challenges to Lodine?
Generic applicants historically could have used Paragraph IV certifications against any unexpired Lodine-related patents listed in the Orange Book. Publicly available product-level litigation records do not establish a current, material Paragraph IV dispute affecting a branded Lodine franchise.
The more relevant conclusion is commercial: any historical Paragraph IV activity has been overtaken by the mature generic market. Lodine no longer presents the type of active patent barrier associated with a recently launched specialty drug.
How strong is the Lodine patent estate?
The present patent estate is weak from a commercial protection standpoint.
| Patent-estate factor |
Assessment |
| Core molecule protection |
Expired or no longer commercially blocking |
| Immediate-release tablets |
Broad generic competition |
| Extended-release formulation |
Historical differentiation, limited current value |
| Method-of-use claims |
Weak protection against substitution and generic labeling strategies |
| Regulatory exclusivity |
Exhausted |
| Manufacturing barriers |
Low to moderate; established small-molecule chemistry |
| Litigation leverage |
Low |
| Ability to sustain branded pricing |
Very low |
Etodolac is a conventional small molecule with established manufacturing processes. Production requires pharmaceutical-quality active ingredient, formulation controls and regulatory compliance, but it does not present the complex biologic manufacturing barriers associated with monoclonal antibodies, cell therapies or recombinant proteins.
What is Lodine’s financial trajectory?
Public filings do not separately report Lodine revenue, making a verified product-level sales series unavailable. Its financial trajectory can be inferred from the product lifecycle and the broader economics of generic NSAIDs.
Branded growth phase
Lodine entered a large and competitive prescription pain market. Its commercial selling points included etodolac’s anti-inflammatory activity, oral dosing convenience and perceived gastrointestinal tolerability relative to some older NSAIDs. The product competed against entrenched medicines with substantial physician familiarity and low manufacturing costs.
Revenue during the branded phase would have depended on:
- Prescription volume in osteoarthritis and rheumatoid arthritis.
- Managed-care formulary access.
- Physician adoption relative to naproxen, ibuprofen and diclofenac.
- Pricing relative to other branded NSAIDs.
- Uptake of Lodine XL.
- Safety perceptions across the NSAID class.
Generic erosion phase
Once generic etodolac became available, the commercial model changed rapidly. Generic substitution reduced the net price per prescription and shifted purchasing power toward pharmacies, wholesalers and payers. The brand’s remaining revenue would have come mainly from residual prescribing, non-substitutable demand, institutional contracts or markets where the brand remained locally available.
The product also faced therapeutic substitution. A patient prescribed etodolac could often be switched to another NSAID without requiring a novel treatment decision. That made Lodine more vulnerable than products with a unique mechanism, orphan indication or narrow therapeutic niche.
Mature generic phase
In the mature phase, value moved from brand ownership to manufacturing scale and distribution efficiency. Generic suppliers compete primarily on:
- Cost of active pharmaceutical ingredient.
- Manufacturing yield.
- FDA compliance.
- Supply reliability.
- Wholesaler and pharmacy contracts.
- Ability to avoid shortages.
This is a low-margin market unless a supplier has scale, constrained competition or temporary supply advantages.
Which companies compete with Lodine?
Lodine competes at two levels: generic etodolac suppliers and alternative NSAID manufacturers.
Direct competitors
The direct competitors are manufacturers of generic etodolac tablets and extended-release products. These products are approved through ANDAs and are typically dispensed under the generic name rather than the Lodine brand.
Therapeutic competitors
| Drug |
Competitive role |
| Naproxen |
Low-cost, widely used NSAID |
| Ibuprofen |
Broad over-the-counter and prescription competition |
| Diclofenac |
Strong anti-inflammatory positioning, multiple dosage forms |
| Meloxicam |
Prescription NSAID with once-daily dosing |
| Celecoxib |
Selective COX-2 competitor with a distinct safety and pricing profile |
| Ketoprofen and other NSAIDs |
Additional substitution options |
Lodine’s competitive position is constrained because the NSAID market has extensive therapeutic interchangeability and low switching costs.
What regulatory risks affect Lodine?
FDA labeling for etodolac includes class-level NSAID risks. These include cardiovascular thrombotic events, gastrointestinal bleeding and ulceration, renal toxicity, hypertension, hypersensitivity reactions and risks during late pregnancy.[1] These warnings affect the entire NSAID category rather than Lodine alone.
The regulatory profile limits premium pricing because prescribers and payers can select among several NSAIDs with broadly comparable risk-management considerations. New FDA action is unlikely to restore branded Lodine value unless a new indication, delivery system or clinical differentiation receives approval.
Are biosimilars relevant to Lodine?
No. Lodine is a chemically synthesized small molecule, not a biologic. Biosimilar competition does not apply. The applicable pathway is generic-drug competition through ANDAs, not the abbreviated biologics license application pathway under the Public Health Service Act.
What generic launch scenarios exist for Lodine?
The principal scenarios are:
- Continued generic commoditization. Multiple suppliers maintain low prices and prevent meaningful branded recovery.
- Supplier consolidation. Fewer manufacturers could raise prices temporarily, but substitution with other NSAIDs would limit sustained pricing power.
- Extended-release niche demand. A manufacturer could retain a small market for once-daily etodolac if reimbursement supports it.
- Supply disruption. A temporary shortage could shift share among generic suppliers without creating durable value for the Lodine brand.
- International variation. Etodolac may remain marketed under local brands in some jurisdictions, but national approval, reimbursement and patent rules differ.
What licensing deals or litigation affect Lodine?
No current licensing transaction or active patent litigation appears to materially affect the U.S. commercial outlook for Lodine. The principal corporate event was Pfizer’s acquisition of Wyeth, completed in 2009.[2] That transaction transferred a broad portfolio of products and did not create a new exclusivity platform for etodolac.
The absence of current material litigation is consistent with the product’s maturity. Patent disputes are more economically rational for high-revenue medicines with remaining exclusivity than for a low-priced generic NSAID.
What is Lodine’s geographic market coverage?
Lodine’s commercial history is primarily associated with the United States, while etodolac has been marketed in other countries under different brand names and local regulatory arrangements. Geographic value depends on:
- Whether the brand remains registered and marketed.
- Local patent expiry.
- Generic substitution rules.
- National reimbursement policies.
- Distributor ownership.
- Manufacturer supply commitments.
A global estimate of Lodine revenue cannot be derived reliably from public company filings because manufacturers generally aggregate mature products into broader geographic or therapeutic categories.
Key Takeaways
- Lodine is the legacy brand for etodolac, an oral NSAID.
- Its U.S. branded exclusivity has expired, and generic etodolac is the principal market form.
- No current patent estate appears to support meaningful branded market protection.
- Product-level Lodine revenue is not separately disclosed in public corporate filings.
- Financial value shifted from branded pricing to generic manufacturing and distribution economics.
- The main competitors are generic etodolac suppliers and alternative NSAIDs such as naproxen, ibuprofen, diclofenac, meloxicam and celecoxib.
- Biosimilar risk is irrelevant because etodolac is a small molecule.
- Current commercial upside is limited unless linked to a new formulation, new indication, supply constraint or geographically protected market.
FAQs
Is Lodine still available in the United States?
Generic etodolac is available in the United States. The original Lodine brand has limited or no material current branded presence compared with generic products.
Is etodolac stronger than ibuprofen?
The drugs cannot be ranked as universally stronger. Clinical response varies by patient, dose, indication and tolerability. Etodolac competes as a prescription NSAID, while ibuprofen is widely available over the counter and by prescription.
Did Pfizer own Lodine?
Pfizer acquired Wyeth in 2009, placing Wyeth’s legacy products within Pfizer’s portfolio. Public filings did not separately report Lodine revenue.
Does Lodine have an active U.S. patent?
No active patent appears to provide meaningful U.S. market exclusivity for conventional Lodine or generic etodolac products.
Can a company relaunch Lodine as a branded product?
A relaunch would face substantial barriers from generic substitution, therapeutic alternatives, limited differentiation and NSAID safety warnings. Commercial viability would likely require a differentiated formulation, delivery system, indication or reimbursement strategy.
References
- U.S. Food and Drug Administration. (n.d.). Etodolac prescribing information. DailyMed.
- Pfizer Inc. (2010). 2009 annual report.
- U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. Orange Book.
- U.S. Food and Drug Administration. (2015). FDA strengthens warning that non-aspirin nonsteroidal anti-inflammatory drugs increase chance of heart attack or stroke.
- U.S. Securities and Exchange Commission. (2009). Pfizer Inc. acquisition of Wyeth and related corporate filings.
